Pre-Made Aldafermin Biosimilar, Recombinant Protein targeting FGFR4: Recombinant therapeutic protein targeting CD334/JTK2/TKF for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Aldafermin Biosimilar, Recombinant Protein targeting FGFR4: Recombinant therapeutic protein targeting CD334/JTK2/TKF is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation, and injury, and is associated with an increased risk of liver transplantation and death. A Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis in patients with non-alcoholic steatohepatitis.
| Products Name (INN Index) | Pre-Made Aldafermin Biosimilar, Recombinant Protein targeting FGFR4: Recombinant therapeutic protein targeting CD334/JTK2/TKF |
|---|---|
| INN Name | aldafermin |
| Target | FGFR4 |
| Format | Recombinant Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | FGF19 (fibroblast growth factor 19) 5- 194 |
| VD LC | FGF19 (fibroblast growth factor 19) 5- 194 |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NGM Biopharmaceuticals, Inc. (South San Francisco CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FGFR4 |
| Package |
